All In Biotech

Drug Trial Radar · NCT06780449

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With Obesity

Last checked: Nov 20, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Feb 10, 2025

Primary completion

Aug 28, 2028

Study completion Oct 31, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jan 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.

Conditions

  • Obesity

Interventions

  • CagrilintideDrug

    Participants will receive cagrilintide subcutaneously.

  • SemaglutideDrug

    Participants will receive semaglutide subcutaneously.

  • Placebo cagrilintideDrug

    Participants will receive placebo matched to cagrilintide subcutaneously.

  • Placebo semaglutideDrug

    Participants will receive placebo matched to semaglutide subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in body weightTime frame: From baseline (week 0) to week 104

Locations

36 sites in 6 countries. Site status is shown where the registry gives one.

  • Valley Clinical Trials

    Covina, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Yale University School Of Medicine

    New Haven, Connecticut

  • East West Medical Research Institute_Honolulu

    Honolulu, Hawaii

  • L-MARC Research Center

    Louisville, Kentucky

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri

  • Spartanburg Medical Research

    Spartanburg, South Carolina

  • Holston Medical Group_Bristol

    Bristol, Tennessee

  • North Texas Endocrine Center

    Dallas, Texas

  • Washington Cntr Weight Mgmt

    Arlington, Virginia

  • Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie

    Brussels, Belgium

  • UZA - UZ Antwerpen - Department of Endocrinology

    Edegem, Belgium

  • UZ Leuven - Endocrinology

    Leuven, Belgium

  • CHU Helora - Hôpital de Mons - Site Constantinople

    Mons, Belgium

  • Alpha Recherche Clinique - Lebourgneuf

    Québec, Canada

  • Dr. M.B. Jones Inc

    Victoria, British Columbia, Canada

  • Nova Scotia Health Authority

    Halifax, Nova Scotia, Canada

  • Premier Clinical Trial Research Network (PCTRN)

    Hamilton, Ontario, Canada

  • Aarhus Universitetshospital, Steno Diabetes Center Aarhus

    Aarhus, Denmark

  • Sydvestjysk Sygehus Esbjerg - Medicinsk Endokrinologisk Ambulatorium, Forskningsenheden

    Esbjerg, Denmark

  • Gentofte Hospital - Center for Klinisk Metabolisk Forskning

    Hellerup, Denmark

  • Hvidovre Hospital Endokrinologisk forsknings afsnit 159

    Hvidovre, Denmark

  • Sjællands Universitetshospital, Køge - Medicinsk Afdeling

    Køge, Denmark

  • APDP - Associação Protectora dos Diabéticos de Portugal

    Lisbon, Portugal

  • CUF Descobertas

    Lisbon, Portugal

  • Hospital Cuf Descobertas S.A.

    Lisbon, Portugal

  • Unidade Local de Saude de Sao Joao E.P.E

    Porto, Portugal

  • Hospital Luz Arrabida, S.A.

    Vila Nova de Gaia, Portugal

  • ULS De Matosinhos E.P.E.- Hospital Pedro Hispano

    Senhora Da Hora, Matosinhos, Matosinhos, Portugal

  • Southmead Hospital

    Bristol, United Kingdom

  • Addenbrooke's Hospital_Cambridge

    Cambridge, United Kingdom

  • University Hospital Coventry - WISDEM Centre

    Coventry, United Kingdom

  • Aintree University Hospital

    Liverpool, United Kingdom

  • Royal London Hospital - Blizard Institute

    London, United Kingdom

  • Joint Clinical Research Facility - Swansea

    Swansea, United Kingdom

  • Musgrove Park Hospital

    Taunton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.